Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,883 Million (Mid Cap)
23.00
NA
0.77%
0.26
10.40%
2.53
Revenue and Profits:
Net Sales:
270 Million
(Quarterly Results - Sep 2025)
Net Profit:
50 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
9.74%
0%
9.74%
6 Months
1.11%
0%
1.11%
1 Year
0.03%
0%
0.03%
2 Years
-23.54%
0%
-23.54%
3 Years
18.48%
0%
18.48%
4 Years
-22.15%
0%
-22.15%
5 Years
-33.23%
0%
-33.23%
Shenzhen Weiguang Biological Products Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.63%
EBIT Growth (5y)
9.65%
EBIT to Interest (avg)
51.08
Debt to EBITDA (avg)
0.63
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.40
Tax Ratio
14.79%
Dividend Payout Ratio
17.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.71%
ROE (avg)
10.33%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.65
EV to EBIT
21.01
EV to EBITDA
14.61
EV to Capital Employed
2.34
EV to Sales
5.52
PEG Ratio
1.27
Dividend Yield
0.75%
ROCE (Latest)
11.13%
ROE (Latest)
11.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
270.40
331.20
-18.36%
Operating Profit (PBDIT) excl Other Income
57.40
119.70
-52.05%
Interest
5.10
5.50
-7.27%
Exceptional Items
0.00
0.00
Consolidate Net Profit
50.20
72.80
-31.04%
Operating Profit Margin (Excl OI)
212.40%
264.90%
-5.25%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is -18.36% vs 19.01% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -31.04% vs 44.16% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,197.60
1,044.10
14.70%
Operating Profit (PBDIT) excl Other Income
438.50
327.60
33.85%
Interest
22.90
15.30
49.67%
Exceptional Items
-14.10
0.70
-2,114.29%
Consolidate Net Profit
254.00
217.50
16.78%
Operating Profit Margin (Excl OI)
265.60%
228.10%
3.75%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.70% vs 57.05% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 16.78% vs 79.46% in Dec 2023
About Shenzhen Weiguang Biological Products Co., Ltd. 
Shenzhen Weiguang Biological Products Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






